AP Gets First Notified Body for Medical Device Manufacturing Facilities Inspection

CDSCO has notified KIHT Certification Services (KCS) inside AMTZ as state’s first regulatory body

Visakhapatnam: Andhra Pradesh is now home to its first-ever CDSCO notified auditing body for medical devices. In a significant move, the Central Drugs Standard Control Organisation (CDSCO) under Minister of Health and Family Welfare, Govt. of India has notified KIHT Certification Services (KCS) as the state’s first regulatory body authorised to inspect manufacturing facilities for Class A and Class B medical devices.

Among 14 such notified bodies nationwide, KCS is the only one operational in Andhra Pradesh and Telangana, marking a milestone in the region’s quality management capabilities. Founded in July 2017, Kalam Institute of Health Technology (KIHT) housed inside the AMTZ campus is a Government of India project supported by the Department of Biotechnology, at promoting and supporting innovations in medical technologies through research and development, industry promotion, policy-making and knowledge repository.

Founded in April 2022, KCS is accredited by the National Accreditation Board for Certification Bodies (NABCB) under ISO/IEC 17021 1:2015 and IAF MD 9:2023 standards. The organisation offers comprehensive services including ISO 13485 certification, quality systems audits, risk management training, and CE mark consultancy—making it a full-service hub for manufacturers seeking to meet global regulatory standards.

This approval brings immediate benefits to domestic manufacturers, particularly MSMEs, by eliminating the need for audits outside the state—resulting in significant time and cost savings. It also reinforces Andhra Pradesh’s MedTech credentials, supporting national campaigns like “Make in India” and “ACI manufacturing,” while making the region highly attractive for future investments. This significant milestone empowers KCS to conduct independent regulatory audits for medical device manufacturers in accordance with the Medical Devices Rules (MDR) 2017 for Class A (low risk) and Class B (moderate risk), the state underscores its reputation as a business-friendly hub, ready to meet rising global demand in healthcare.

Related Posts

India’s Pharma Sector Must Expand AI Use Beyond R&D: Reports

The report emphasizes that absolute R&D spending remains modest and identifies expanding investment in advanced biologics and AI-driven drug discovery as the “largest opportunity” for bridging the innovation divide. Recent…

India’s Pharma, Healthcare Funding Hits $38.6 Mn in Nov’25

Early-stage activity drove the month, accounting for 73.6 per cent of total investments, while seed-stage rounds contributed the remaining 26.4 per cent. India’s pharma and healthcare funding for November 2025…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

India’s Pharma Sector Must Expand AI Use Beyond R&D: Reports

India’s Pharma Sector Must Expand AI Use Beyond R&D: Reports

India headed for Culture of ‘Divya Buildings’, thanks to AMTZ’s Landmark Initiative

India headed for Culture of ‘Divya Buildings’, thanks to AMTZ’s Landmark Initiative

India’s Pharma, Healthcare Funding Hits $38.6 Mn in Nov’25

India’s Pharma, Healthcare Funding Hits $38.6 Mn in Nov’25

Novo Nordisk gears up for December Ozempic launch

Novo Nordisk gears up for December Ozempic launch

Illegal intoxicant tablets seized in large quantity from Sirsa medical store, two held

Illegal intoxicant tablets seized in large quantity from Sirsa medical store, two held

Higher pharma, chemicals exports to Russia bloc on agenda to trim deficit

Higher pharma, chemicals exports to Russia bloc on agenda to trim deficit